Skip to content

NVS

Novartis AG

NYSE · Healthcare · Drug Manufacturers - General · CH

$163.58
+2.71%
Ask drillr

Year over year

Reported trailing growth

Revenue
-0.1%
EBITDA
-5.0%
EBIT
-18.4%
EPS
-28.7%
Free cash flow
-13.0%
Operating cash flow
-17.8%

Forward estimates

Based on analyst estimates

Revenue
+6.2%
EBITDA
+58.9%
EPS
+86.3%

Three-year CAGR

Revenue
+8.0%
EBITDA
+16.1%
EBIT
+29.0%
Net income
+26.4%
EPS
+31.5%
Free cash flow
+13.8%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026